Pot stocks soar as new deals done – SBS

Australia’s listed medical marijuana sector has had a strong day with gains for three companies announcing new deals.

AusCann shares soared after its Chilean joint-venture secured approval for a new crop.

The Chilean government issues licences for medicinal cannabis cultivation for one year periods, and AusCann’s joint-venture partner, Fundacion Daya, has been awarded the only licence for each of the past four years.

The licence allows the joint venture, DayaCann, to start cultivating its second crop at its 30-hectare facility south of Santiago in Chile, following a first crop of more than 400kg earlier this year.

AusCann managing director Elaine Darby said the expansion will help the company become a fully integrated operation serving the Australian and Latin American markets.

“Chile is one of the regions at the forefront of change, and access to cannabis medications for patients in need is advancing rapidly in the region,” she said in a statement.

Another listed play, cannabis-based medicines and nutritional product developer Creso Pharma, announced it will import its first human health product into Australia in 2018.

The product, cannaQIX50, is a cannabidiol lozenge for chronic pain management and will be distributed to pharmacies in Australia by Health House International.

Creso said the importation is part of a strategy to expand the international distribution of its products.

The lozenges will be available through the Therapeutic Goods Administration’s Special Access Scheme, which allows eligible doctors to apply for approval to prescribe medicinal cannabis products.

Meanwhile MGC Pharmaceuticals announced it had signed a deal with European medical marijuana product maker Mabsut Life to supply its cannabis-based extract for use in electronic cigarettes.

Mabsut Life will use MGC’s cannabidiol extract to develop an e-cigarette cartridge formula and will use the product under its own electronic cigarette brand, which is sold in central and eastern Europe.

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Pot stocks soar as new deals done – SBS

Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today – Madison.com

What happened

After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW Pharmaceuticals (NASDAQ: GWPH) jumped 11.1% today.

GW Pharmaceuticals recently completed filing for Food and Drug Administration approval of Epidiolex, a cannabidiol medicine that’s being evaluated for use in patients with two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome.

IMAGE SOURCE: GW PHARMACEUTICALS.

Today, the company’s management unveiled updated trial data ahead of an industry conference next month. The data shows that 35% of Lennox-Gastaut syndrome patients responded to Epidiolex monotherapy, but only 13% of patients responded to a placebo. The news is important because it helps address how much of the treatment benefit observed previously was due to Epidiolex’s use alongside clobazom, a common epilepsy medicine. 

Data was also provided from a long-term extension from a single-arm study showing a significant improvement from baseline in patients. In Dravet syndrome patients, there was a 57% to 59% reduction in total monthly seizures at week 60. In Lennox-Gastaut syndrome patients, there was a 62% to 70% drop in seizures from baseline at week 60. In both cases, the data suggests that Epidiolex efficacy remains positive over time. 

The FDA filing for Epidiolex’s approval was prompted by the drug reducing monthly seizures by about 40% from baseline and this data adds conviction that doctors will prescribe it if it wins FDA approval next year.

An approval in Dravet syndrome and Lennox-Gastaut syndrome patients would be important for GW Pharmaceuticals because it doesn’t generate much in the way of revenue from its THC-based drug Sativex, which is approved in Europe for use in MS spasticity patients.

The big prize,

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today – Madison.com

Upcoming Seasonal Anomalies: A Marijuana Stock Focus – Seeking Alpha

It was really a pleasure to read Ted’s recent Seeking Alpha article and participate in the comments, where a few were interested in my thoughts on the U.S. side of tax loss selling. That is what motivated me to write this article. I hope you find it interesting.

Tax Loss Selling to Match Losses with Gains and Avoids the Need for Liquidity

Tax loss selling is part of a portfolio rebalancing process that is calendar year end and tax motivated. It stems from a need to “match” losses from “losers” in your portfolio with the “winters” to reduce cash outflows to pay capital gains taxes in the following calendar year, and around April 15 in the U.S. John Maynard Keynes would refer to this as being motivated to avoid the need for “liquidity.”

Source: TOP 25 LIQUIDITY QUOTES | A-Z Quotes

Leaving the Canadian Side to Ted, but Focusing on the U.S. in my SA Portfolio

I am going to leave the Canadian side of marijuana [MJ] or cannabis stocks to Ted. I only focus on these stocks to the extent that they are represented on U.S. exchanges, and include quite a few of the “penny” or micro-cap MJ stocks. The below are upcoming U.S. stock exchange holidays:

I have merged some monthly calendars to make it easier to see these stock exchange holidays and the seasonal anomalies that have occurred in the past.

Some Upcoming Seasonal Anomalies

First, note that the day after Thanksgiving is a half-trading day on November 24, 2017 (see above table).

Second, based on data I developed from the 2016 calendar year, I would expect the “bottom” for marijuana stocks to be normally distributed on or about December 20-21, 2017. Does this mean this will happen for all stock for 2017? Of course

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Upcoming Seasonal Anomalies: A Marijuana Stock Focus – Seeking Alpha

A New Marijuana ETF Is Coming to the New York Stock Exchange – Hacked

Very few investment communities are as confident about their long-term prospects as the backers of bitcoin, according to a recent survey conducted by LendEDU. Whether buying the dip, holding for long-term gains or cost-averaging each month, bitcoin investors believe the bull market has only just begun.

Americans Excited About Bitcoin

Americans are highly bullish on bitcoin, according to LendEDU’s most recent survey of 564 respondents. The survey results indicated that most holders of the cryptocurrency have no plans to exit their positions anytime soon.

When asked, “At what price per bitcoin would you be willing to sell all of your bitcoin investment?”, the average response was tallied at $196,165.79.

You read that correctly. Americans are prepared to ride out the bitcoin rally until prices reach $200,000.

At the time the survey was taken, bitcoin was valued at around $6,500, LendEDU said. That means prices would need to rise more than 2,900% for the average respondent to consider unloading their digital assets.

The survey also found that the average bitcoin investment account held a little less than $3,000, with more than 60% of respondents having had exposure to the cryptcurrency for more than one year. Only about a third (32.62%) of poll-takers said they have sold some or all of their bitcoin investment since the began the venture.

Twenty-one percent of respondents said they’ve invested in bitcoin because it is “a long term store of value, like gold or silver.”

Bitcoin’s Future Valuation

Forecasting bitcoin’s long-term price trajectory is no simple task, but that hasn’t stopped industry proponents from giving lofty valuations about where the digital currency is headed. Last month, serial strategist Tommy Lee said $25,000 was too conservative of a price point for bitcoin.

John McAfee, who plans to launch his own cryptocurrency, believes bitcoin is already headed to $500,000. He believes

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on A New Marijuana ETF Is Coming to the New York Stock Exchange – Hacked

Ranking the Top 4 Canadian Marijuana Stocks – The Motley Fool Canada

Canadian marijuana stocks are hot again. Although shares have surged exponentially over the last few months, there’s still room to run for investors with long-term time horizons (of at least five years). If you’ve got an extremely high risk tolerance and the discipline to handle huge amounts of volatility, then you may be wondering which marijuana stocks will be your best bet in the months and years following legalization day.

In ascending order, here’s what I believe will be the best pot stocks to own for the long haul:

4. Aphria Inc. (TSX:APH)

Aphria is an incredibly efficient producer with a management…

Canadian marijuana stocks are hot again. Although shares have surged exponentially over the last few months, there’s still room to run for investors with long-term time horizons (of at least five years). If you’ve got an extremely high risk tolerance and the discipline to handle huge amounts of volatility, then you may be wondering which marijuana stocks will be your best bet in the months and years following legalization day.

In ascending order, here’s what I believe will be the best pot stocks to own for the long haul:

4. Aphria Inc. (TSX:APH)

Aphria is an incredibly efficient producer with a management team that has done an absolutely fantastic job of driving costs down (dried cannabis production costs down 4% to $1.60/gram). Although we’re still in the very early stages of an emerging industry and marijuana is not yet legal, Aphria has been making a statement with its soaring earnings and industry-leading efficiency results.

The company clocked in a net income of $15 million for its fiscal Q1 2018, over 16 times higher than the same quarter a year before.

Based on the fundamentals, Aphria looks like a clear winner; however, it’s last on the list because of uncertainties over

Read More Here...

Posted in Hemp, MMJ, Cannabis Stocks News | Comments Off on Ranking the Top 4 Canadian Marijuana Stocks – The Motley Fool Canada
« Older